Fox Run Management L.L.C. Purchases Shares of 12,308 Glaukos Corporation $GKOS

Fox Run Management L.L.C. purchased a new position in shares of Glaukos Corporation (NYSE:GKOS) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 12,308 shares of the medical instruments supplier’s stock, valued at approximately $1,004,000.

A number of other large investors also recently modified their holdings of GKOS. UMB Bank n.a. increased its position in shares of Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 158 shares during the last quarter. REAP Financial Group LLC bought a new position in Glaukos in the third quarter valued at approximately $40,000. AlphaQuest LLC increased its position in shares of Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 633 shares during the last quarter. SBI Securities Co. Ltd. increased its position in shares of Glaukos by 42.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock worth $98,000 after purchasing an additional 362 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in shares of Glaukos by 16.2% during the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 136 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Performance

NYSE GKOS opened at $121.62 on Friday. The stock has a market cap of $7.06 billion, a PE ratio of -37.31 and a beta of 0.70. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69. The firm has a 50-day moving average of $115.92 and a 200-day moving average of $99.78. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $130.23.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The company had revenue of $143.12 million during the quarter, compared to analyst estimates of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The firm’s quarterly revenue was up 35.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.40) EPS. On average, sell-side analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Insider Buying and Selling

In other Glaukos news, Director Aimee S. Weisner sold 15,000 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $117.38, for a total value of $1,760,700.00. Following the transaction, the director directly owned 18,806 shares of the company’s stock, valued at $2,207,448.28. This represents a 44.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Thomas William Burns sold 186,945 shares of the stock in a transaction on Friday, January 16th. The stock was sold at an average price of $115.00, for a total value of $21,498,675.00. Following the transaction, the chief executive officer owned 153,775 shares in the company, valued at $17,684,125. The trade was a 54.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 325,000 shares of company stock valued at $37,739,259 in the last ninety days. 5.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on GKOS. Truist Financial raised their target price on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. UBS Group increased their price target on shares of Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. The Goldman Sachs Group restated a “buy” rating and set a $138.00 price objective on shares of Glaukos in a research note on Friday, January 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $165.00 target price on shares of Glaukos in a report on Wednesday, January 14th. Finally, William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and a consensus target price of $133.69.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.